Study Title
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma (NCT00866047)
Trial Description
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (also known as SGN-35) as a single agent in patients with relapsed or refractory ALCL.
This trial is sponsored by Millennium Pharmaceuticals/ Seattle Genetics. [1]
Study Data
- Conditions:
- Large-Cell Anaplastic Lymphoma
- Non-Hodgkin’s Lymphoma (NHL)
- Interventions:
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- Drugs used in this trial
- Phase: II
- Enrollment: 58
- Start: March 2009
- Estimated Completion: June 2016
- Last verified: March 2015
Study Schematic
Click here to Return to Drug map
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
